The company will be adding liquid nitrogen storage capabilities at the Berlin site in phase two of the expansion, set to begin in FY 2022
PCI Pharma Services has announced an expansion of the cold chain clinical supply storage and distribution capabilities at its Berlin location, an investment aimed to provide global access to regional customers. The facility recently passed mandatory regulatory inspection for these expansions and is now operational.
The company has added capacity and several cold chain storage conditions to its capabilities, which now include temperatures from controlled room temperature to -80°C. It has doubled the size of its 2-8°C storage and added -20°C and -80°C.
The Berlin facility is now congruent with the company’s global facilities, helping it support the vaccine supply chain and keep pace with growing demands for biologic therapies. The added Berlin capacity is designed to service small-to-medium sized pharmaceutical companies within mainland Europe, which are conducting clinical trials in the EU, as well as in North America and other parts of the world.
“We look forward to welcoming clients to use the newest expansion in our network, part of a larger strategy to ensure that we have capacity to meet the needs of the clinical market as it evolves,” said Brian Keesee, VP and General Manager, Global Clinical Operations and Supply, PCI Pharma Services. “These expanded capabilities and breadth of offerings will ensure that our global and mainland EU customers conducting clinical trials, particularly those in the DACH region of Austria, Germany, and Switzerland, have the support of a full-service solution, which the industry prefers, in a prime location with excellent transport hubs.”
This announcement marks the latest in series of global clinical expansions the company has made across multiple continents and four other sites, including San Diego; Rockford, Illinois; Bridgend, U.K.; and Australia. PCI completed a clinical centre of excellence at its Berlin location in July 2020, following the acquisition of Bellwyck Pharma Services in early 2020.